We couldn't find that disease.
New drug combo shows promise against Hard-to-Treat hepatitis c
NCT ID NCT00630058
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-phase trial tested a new hepatitis C drug called telaprevir (MP-424) combined with two standard medications (peginterferon and ribavirin) in 20 people with genotype 1b hepatitis C. The main goals were to check safety and how the drug moves through the body. Researchers also measured how well the combo lowered virus levels. The study was completed and helped guide later, larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telaprevir (MP-424) plus peginterferon alfa-2b and ribavirin
What this could lead to
If successful, this could point toward a more effective treatment for hepatitis C genotype 1b, potentially leading to higher cure rates.
What could go wrong
This was a very early phase 1 study with only 20 participants, so results may not apply to everyone. The combination also carries known side effects like fatigue and anemia.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.